Overview

Protocol for the Treatment of Metastatic Ewing Sarcoma

Status:
Active, not recruiting

Trial end date:
2021-11-30

Target enrollment:

Participant gender:

Summary

Study for the treatment of metastatic Ewing sarcoma with high doses chemotherapy, radiotherapy and maintenance therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Italian Sarcoma Group

Treatments:

Busulfan
Cyclophosphamide
Doxorubicin
Etoposide
Etoposide phosphate
Ifosfamide
Irinotecan
Isophosphamide mustard
Liposomal doxorubicin
Melphalan
Temozolomide
Vincristine